cyrilzakka/clinical-trials huggingface dataset:
Effects of Postural Correction Exercises in Reducing Forward Head Posture in Children Carrying Heavy Bag Packs

This study aims to investigate the effectiveness of a 4-week postural correction exercise program in reducing FHP in children carrying heavy backpacks to school. This study's findings could have significant implications for preventing musculoskeletal problems associated with FHP. Furthermore, the study's findings could inform healthcare professionals and educators about the importance of promoting healthy postures among children and adolescents to prevent long-term musculoskeletal problems. This is an experimental study. Subjects will be divided into two groups. Group A (control group) and group B (experimental group).fun activities will be performed by experimental group under the supervision of the therapist.

Regular use of heavy school bags and inappropriate carrying methods can put children at the risk of musculoskeletal problems and changes the body posture. It is imperative to note that carrying a backpack more than the recommended weight limit poses a twofold hazard, particularly to children and adolescents who are undergoing neuromusculoskeletal development and growth. Hence, it is crucial to ensure that the backpack's weight does not exceed 10-15% of the child or adolescent's body weight. Overreaching this weight limit may result in posterior displacement of the center of gravity, thereby engendering augmented strain on the neck and back muscles. Such effects are commonly linked with spinal column pathologies and reduced lung volume.One of the most prevalent types of postural anomaly is called "forward head posture" (FHP), and it is typically characterized by the head being anterior to the body's vertical line gravity point. Chronic FHP issues develop from an excessive load being placed on the joint and muscle when cervical muscular imbalances brought on by postural misalignment are left untreated. Both an upper cervical extension and a lower cervical flexion define forward head position. These modifications in the cervical region could result in long-term bad head posture, which could cause "upper crossed syndrome" or other musculoskeletal disorders. Additionally, neck and shoulder pain are common complaints among FHPs patients . Numerous studies have shown that carrying a backpack that is 7.5% of or more of your body weight (BW) causes postural compensations. The increased weight of the backpack correlates with higher FHP, trunk flexion, spinal asymmetry, and tensile forces in the intervertebral discs under static settings

Eligibility Criteria:
Inclusion Criteria:

* Both gender
* Children who carry heavy backpacks to school (more than 10% of their body weight)
* Forward head posture, defined as a craniovertebral angle of less than 50 degrees.
* Willing to participate in the study.
* Consent obtained from parents or legal guardians

Exclusion Criteria:

* Cervical spine fracture or neurological disorder.
* Scoliosis or torticollis.
* Joint hypermobility or recent surgery . Prior history of physical therapy treatment for forward head posture in the past six months
A Pilot Study of a Community Health Agent-led Diabetes Self-Management Program

This was a pilot study to assess the feasibility and acceptability of training Community Health Agents in Motivational Interviewing in real-life primary care centers.

Rates of noncommunicable diseases (NCDs) such as type 2 diabetes are escalating in low and middle-income countries such as Brazil. Scalable primary care-based interventions are needed to improve self-management and clinical outcomes of adults with diabetes. This pilot study examines the feasibility, acceptability, and outcomes of training community health agents (CHAs) in Motivational Interviewing (MI)-based counseling for patients with poorly controlled diabetes in a primary care center in São Paulo, Brazil.

Nineteen salaried CHAs participated in 32 hours of training in MI and behavioral action planning. With support from booster training sessions, they used these skills in their regular monthly home visits over a 6 month period with 57 diabetes patients with baseline HbA1cs \> 7.0%. The primary outcome was patients' reports of the quality of diabetes care as measured by the Portuguese version of the Patient Assessment of Chronic Illness Care (PACIC) scale. Secondary outcomes included changes in patients' reported diabetes self-management behaviors and in A1c, blood pressure, cholesterol and triglycerides. CHAs' fidelity to and experiences with the intervention were also assessed.

Eligibility Criteria:
Inclusion Criteria:

* Adult patients with T2 diabetes who received care at the primary care center
* A1c\>7.0% in prior six months

Exclusion Criteria:

* Age\> 75
* being pregnant
* having terminal health condition or other conditions that would impede participation such as dementia and mental illness
Metabolic Syndrome Cohort in Korea

Patients with metabolic syndrome living in Seoul area are included in this prospective registry for more than 10 years. All enrolled patients undergo thorough medical history survey. Enrolled patients will have coronary CT, 2D echocardiogram, treadmill test, pulse wave velocity, augmentation index, carotid intima-media thickness, and abdominal fat mass evaluation. Moreover, lipid profiles and inflammatory markers such as hsCRP, IL-6, TNF-alpha, VCAM-1, ICAM-1, adiponectin, MMP-9 will be measured. All participants will repeat the test and survey every year in Korea University Hospital.


Eligibility Criteria:
Inclusion Criteria: 3 out of 5 criteria

* Central obesity: Men ≥ 90 cm Women ≥ 85 cm
* Plasma triglycerides ≥ 150 mg/dL
* HDL cholesterol Men \< 40 mg/dL, Women \< 50 mg/dL
* Blood pressure ≥130/85 mm Hg (or treatment for hypertension)
* Fasting plasma glucose ≥ 100 mg/dL
* Age between 30 to 64
* Consent to our registry protocol

Exclusion Criteria:

* Patients who could not undergo coronary CT, 2D echocardiogram, treadmill test, and pulse wave velocity.
HCV Related Hepatocellular Carcinoma Recurrence After Directly Acting Antivirals: A Randomized Controlled Trial

Data regarding hepatocellular carcinoma (HCC) recurrence after directly acting antivirals (DAAs) given for hepatitis C virus treatment are contradictory. Surprisingly, some studies reported that DAAs are accompanied with higher HCC recurrence. But, other studies showed no rise or even decrease in HCC recurrence. Most of these studies were retrospective and some were non-randomized prospective studies. Here investigators aim to perform a randomized controlled trial to study this issue.


Eligibility Criteria:
Inclusion Criteria:

* Child-Pugh A and B subjects with hepatitis C related \< 5 cm single or up to 3 hepatocellular carcinomas without any vascular or extrahepatic involvement

Exclusion Criteria:

* Those with positive HBsAg, history of alcohol consumption, patients with other known causes of chronic liver disease, patients who have received previous DAAs for HCV and patients who have received previous locoregional treatment for HCC will be excluded.
LPB Combined with QLB Using Single-needle Technique (LPQLB-SNT) for Hip Arthroplasty

Total hip arthroplasty (THA) is one of the most successful orthopedic procedures to effectively relieve pain and restore function in patients with hip osteoarthritis, osteonecrosis of femoral head and hip fracture.The Lumbar Plexus Block (LPB) is currently used as the standard regional anesthesia technique to provide postoperative pain management after THA. The lumbar plexus (LP) originates from T12 to L5. In general, multiple-needle nerve blockade procedure is needed to block different branches of LP. Therefore, we need more time to finish the regional anethesia procedure and it's not easy for an inexperienced anesthesiologist to master the technique absolutely. In addition, multiple injections will increase the discomfort of the patients. We aim to investigate the effects of lumbar plexus combined with quadratus lumborum block using single-needle technique with Shamrock method as an alternative regional anesthesia.


Eligibility Criteria:
Inclusion Criteria:

1. Body mass index (BMI) between 18.5 and 30kg/m2 and the weight ≥50kg
2. American Society of Anesthesiologists (ASA) classification I-II
3. Postero-lateral operative incision approach unilateral hip arthroplasty
4. Aged 18-75

Exclusion Criteria:

1. Patient refusal
2. Patients with coagulopathy or on therapeutic anticoagulation
3. Pregnancy
4. Multiple trauma
5. Hypersensitivity or allergy to ropivacaine
6. History of ankylosing spondylitis or spinal surgery
7. Lower extremity neuropathy
8. Unable to communicate
Metabolic Phenotyping of Individuals Born Following Assisted Reproduction Techniques

This study is to compare the effects of high fat overfeeding on metabolic risk factors in children born though assisted reproduction technologies (ART) versus children conceived naturally (controls). The investigators will utilize state of the ART measures to characterize the physiological, endocrine and molecular responses to high fat overfeeding.

The investigators hypothesize that children conceived following ART will have greater responses to high fat dietary challenge and that this will be associated with DNA hypermethylation of genes that are involved in lipid metabolism.

This study represents a novel initiative by the investigators to determine whether children conceived through ART have different metabolic responses at baseline or in response to high fat overfeeding as compared to age and body mass index-matched spontaneously conceived controls. Furthermore, the investigators will identify any differences in DNA methylation of candidate genes involved in lipid metabolism in adipose tissue and blood, to determine whether this is related to adverse outcomes during high fat overfeeding. The results from this study will help answer growing questions of the future health of In vitro fertilisation (IVF) babies, and may stimulate further research into optimising protocols for ovarian stimulation or in-vitro conditions during early blastocyst development.

Eligibility Criteria:
Inclusion Criteria:

* Post-pubertal healthy individuals aged 18-25years

Exclusion Criteria:

* Participants are ineligible if they have any significant medical conditions (e.g. personal history or clinical manifestation of cardiovascular disease, type 2 diabetes),
* strong family histories of diabetes or cardiovascular disease (e.g. first-degree relatives),
* take concomitant medications (eg: metformin),
* if they smoke or drink \>140g of alcohol/week, , or
* were born prematurely (\<37 weeks), or
* from mothers who had gestational diabetes.
Quantitative MRI for Myelofibrosis

This study is for the development and validation of functional magnetic resonance imaging (MRI) parameters as biomarkers for analyzing extent of disease and quantifying response to treatment in patients with myelofibrosis.

This study is for the development and validation of functional magnetic resonance imaging (MRI) parameters as biomarkers for analyzing extent of disease and quantifying response to treatment in patients with myelofibrosis. Quantitative MRI parameters for diffusion of water and/or fat content in bone marrow will determine extent of disease in patients with myelofibrosis, and changes in these parameters will predict response to therapy. To investigate this hypothesis, the researchers will perform this pilot clinical study of diffusion and fat content (T1 weighted imaging) in patients before and during treatment for myelofibrosis. The researchers expect to identify MRI parameters that determine the extent and severity of bone marrow disease in these patients and determine response to therapy at earlier time points than currently used clinical parameters. This research will lay the foundation for larger clinical trials using MRI to assess and predict effects of existing and new therapeutic agents for patients with myelofibrosis.

This study proposes that more advanced MRI techniques currently used in clinical medicine can be applied to enable response to therapy to be determined earlier than currently is possible for patients with myelofibrosis. In particular, this study is designed to determine to what extent abnormalities in diffusion of water molecules (diffusion MRI) and/or fat content in bone marrow (T1-weighted imaging) define extent of initial disease and serve as early predictors of response to therapy.

Eligibility Criteria:
Inclusion Criteria:

1. Male /female subjects over the age of 18
2. Diagnosis of primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis.
3. No contraindications to MRI
4. Able to undergo MRI without anesthesia

   -

Exclusion Criteria:

1. Patients with pacemakers or other implanted magnetic devices that may malfunction or move because of the strong magnetic field inside the MRI room and scanner.
2. Any prior adverse event associated with MRI that is not related to injection of contrast agents or other medicines.

   -
Study of the Pathogenesis of Olfactory Disorders in COVID-19

This study is a case-control study to characterize the molecular and cellular anomalies of the olfactory epithelium of COVID-19 patients with isolated anosmia, by comparison with the olfactory epithelium of non-infected subjects.

Olfactory and taste dysfunctions are common and early onset in COVID-19, especially in pauci symptomatic patients, and may be the main clinical manifestations of the infection. Olfactory dysfunction could result from infection of the olfactory system by SARS-CoV-2 or from inflammation induced by the virus. While the recent development of COVID-19 pulmonary lesion research has revealed a viral, inflammatory and vascular origin, factors that cause olfactory disorders in COVID-19 are just beginning.

Acute anosmia observed in some patients with COVID-19 could result from:

* the direct infection of olfactory sensory neurons or neural stem cells of the olfactory mucosa,
* an underlying inflammation of the olfactory mucosa, leading to possible neurodegeneration of olfactory sensory neurons, and neural stem cells of the olfactory mucosa, by analogy with the respiratory viruses responsible for chronic rhinosinusitis.

It is therefore necessary to conduct a virological, cellular, immunological and inflammatory study of the olfactory epithelium from COVID-19 patients with isolated anosmia to identify the origin of these olfactory disorders.

This study is a case-control study to characterize the molecular and cellular anomalies of the olfactory epithelium of COVID-19 patients with isolated anosmia, by comparison with the olfactory epithelium of non-infected subjects.

Following measures will be performed at inclusion :

* Taste and olfactory function evaluation by a self-questionnaire taste and smell survey (TTS) and a visual analogue scale (VAS)
* Nasal swab sampling for collection of epithelium cells and olfactory mucus.

Eligibility Criteria:
Inclusion Criteria:

COVID-19 patients

* Age \> 18 years
* Subject consulting in the context of the COVID-19 screening care for a suspected SARS-CoV-2 infection

Controls

* Age \> 18 years
* Subject consulting in the ear, nose and throat department with no biologically confirmed COVID-19 or suspected COVID-19 in the past 8 weeks, and no symptoms suggestive of COVID-19 or another respiratory disease and therefore no recent anosmia or ageusia

Exclusion Criteria (both COVID-19 patients and controls):

* Refusal or contraindication to nasal swab
* Presence of nasal sinus pathology
Assessment of Effectiveness and Safety of Dysport® for the Treatment of Hemifacial Spasm

To compare the effectiveness and safety of Dysport® with the domestic Botulinum Toxin Type A (manufactured by Lanzhou Biologic Product Institute, P.R. China) for the treatment of hemifacial spasm.


Eligibility Criteria:
Inclusion Criteria:

* Patient suffering from hemifacial spasm with at least 6 months duration (prior to visit 1)
* Cohen scale ≥ to grade II

Exclusion Criteria:

* Botulinum toxin type A treatment history within last 16 weeks prior to visit 1
* Hemifacial spasm secondary to facial palsy
* Previous alcohol or phenol injections or surgical therapy of the facial muscles
* Requirement for botulinum toxin injection to site(s) of the body other than in this study
Trial to Evaluate Tibolone in the Treatment of Osteoporosis (P06468)

Tibolone 1.25 mg is an effective treatment for the prevention of osteoporosis and is expected to be effective in preventing fractures in osteoporotic women. Tibolone could be more acceptable for long-term use, in particular since it does not induce a regular withdrawal bleed.

The objective of this trial is to compare placebo and tibolone, a steroid with tissue specific activity, in the prevention of spinal fractures in women meeting the WHO criteria for osteoporosis or who have asymptomatic vertebral fractures.


Eligibility Criteria:
Inclusion Criteria:

* Voluntary written informed consent, and who were willing and able to make reasonable efforts to observe all clinical trial requirements were to be enrolled
* Subjects were to be postmenopausal (naturally or surgically) women, from 60 to 85 years of age (inclusive) at entry
* Screening BMD of the total hip and/or spine had to be equal to or lower than 2.5 SD T-score for subjects without an asymptomatic fracture or equal to or lower than -2.0 SD T-score for subjects with an asymptomatic fracture
* Subjects were to have a Body Mass Index (BMI) = 34 kg/m\^2.

Exclusion Criteria:

Subjects with any of the following conditions were not to be enrolled into the trial:

* Recent acute vertebral fracture (diagnosed within the last year) documented by spinal radiograph requiring medication for osteoporosis treatment, in the judgment of the investigator
* More than two prevalent asymptomatic vertebral fractures at baseline
* Screening BMD of the total hip or spine lower than -4 SD T-score
* Unsuitable anatomy on spinal radiographs (lumbar and thoracic vertebrae) e.g., excessive scoliosis
* Not ambulatory
* History or presence of any malignancy within the past five years except for nonmelanoma skin cancer. Subjects with ever history of ovarian cancer or estrogen dependent tumors particularly breast or endometrial cancer were to be excluded
* Trans vaginal ultrasound (TVUS) endometrial double wall thickness \>4 mm
* Unexplained abnormal vaginal bleeding in the past year prior to screening
* Abnormal cervical Papanicolaou (Pap) smear (including low grade squamous intraepithelial lesion (LSIL), high grade squamous intraepithelial lesion (HSIL), atypical squamous cells of undetermined significance (ASCUS), atypical glands of undetermined significance (AGCUS))
* Mammography finding that was suspicious of malignancy
* Bone disease other than osteoporosis such as Paget's disease, osteomalacia, hyperparathyroidism, or bone metastases
* Treatment with anabolic steroids, calcitonin, raloxifene, tamoxifen, or calcitriol within the last six months prior to screening BMD or spinal X-ray measurements.
* Treatment with systemic estrogen and/or progestin within the last three months prior to screening BMD or spinal X-ray measurements (occasional use of estriol containing vaginal cream was allowed)
* Treatment with bisphosphonates for one month or more within the last year
* Ever use of estrogen and/or progestin containing implants
The IMPROVE Study-IMPact of a Regulated ADC System

An automated dispensing cabinet (ADC) is a computerized drug storage device or cabinet designed for hospitals. ADCs allow medications to be stored and dispensed near the point of care while controlling and tracking drug distribution.This study seeks to obtain quantitative measurements of the impact of the regulated ADC System installed in select high volume units throughout the hospital.

The goal of this study is to evaluate the impact of the regulated ADC Systems on the medication administration processes. HackensackUMC is specifically interested in measuring the time to first dose administration from scheduled dosing times of the IV antibiotic piperacillin and tazobactam for injection, USP. and we are interested in assessing a reduction in time from scheduled dosage times of first dose to documented administration after the implementation of the regulated ADC system compared to before.

Timely administration of antibiotics improves morbidity, mortality, and length of hospital stay.Early and effective antibiotic therapy is essential in the management of infection in critical illness. The loading dose is probably the most important dose and is a function of the volume of distribution of the drug and the desired plasma concentration but independent of renal function.

Eligibility Criteria:
Inclusion Criteria:

* Subjects treated at study site in units where regulated ADC System was installed where greater number of medications is administered due to patient volume per nurse assignment or where greater throughput occurs
* Time-sensitive scheduled medications administered on units where administration includes the use of the medication label printer
* Piperacillin and tazobactam for injection, USP (United States Pharmacopeia)
* All IV antibiotics
* Insulin
* Heparin

Exclusion Criteria:

* Medication administration data prior to January 1, 2013;
* Medication administration data after March 31, 2013 through December 31, 2013;
* Medication administration data after March 31, 2014.
Extension Study of NS-089/NCNP-02 in DMD

This is the extension study of NS-089/NCNP-02 (Study NCNP/DMT02), which is designed to assess the safety, tolerability and efficacy of NS-089/NCNP-02 in patients with Duchenne muscular dystrophy (DMD).


Eligibility Criteria:
Inclusion Criteria:

1. Patient completed Study NCNP/DMT02

Exclusion Criteria:

1. Patient had any serious adverse events in Study NCNP/DMT02 that, in the opinion of the Investigator and/or Sponsor, was probably or definitely related to NS-089/NCNP-02 use and precludes safe use of NS-089/NCNP-02 for the patient in this study.
2. Patient had a treatment which was made for the purpose of dystrophin or dystrophin-related protein induction after completion of Study NCNP/DMT02.
3. Patient took any other investigational drugs after completion of Study NCNP/DMT02.
4. Patient was judged by the investigator and/or the Sponsor that it was not appropriate to participate in the extension study for other reasons.
Clinical Performance of a Silicone Hydrogel Contact Lens Following One Night of Extended Wear

The purpose of this clinical study is to evaluate the on-eye performance of an investigational soft contact lens compared to a commercially available soft contact lens following 1 night of extended wear.

Subjects will be randomized to wear the investigational contact lens in 1 eye and the commercially available contact lens in the other eye. Subjects will be expected to attend 4 scheduled study visits. The lenses will be worn continuously from the time of dispense on Day 1 until lens collection at the Day 2 Follow-up/Exit Visit.

Eligibility Criteria:
Key Inclusion Criteria:

* Able to understand and sign an approved Informed Consent form.
* Successful wear of spherical soft contact lenses in both eyes during the past 3 months for a minimum of 5 days per week in either a daily wear or extended wear modality.
* Best Corrected Visual Acuity (BCVA) of 20/25 or better in each eye.
* Other protocol-specified inclusion criteria may apply.

Key Exclusion Criteria:

* Any condition, use of medications, or surgery that could contraindicate contact lens wear, as determined by the Investigator.
* Current Biofinity® lens wearer.
* Pregnant or breast-feeding.
* Other protocol-specified exclusion criteria may apply.